The global blood testing market size was valued at USD 100.7 billion in 2025 and is projected to grow from USD 107.80 billion in 2026 to USD 185.91 billion by 2034, registering a CAGR of 7.05% during the forecast period from 2026 to 2034. North America dominated the blood testing market with a market share of 38.5% in 2025.
The procedure of examining a person's blood to identify and track various medical disorders is called "blood testing" in the global market. In today's medicine, blood tests are crucial for disease diagnosis, treatment efficacy monitoring, and risk factor screening. Blood testing examines various components in the blood or counts different types of blood cells. Blood tests are prescribed to check disease pathogens or agents, check for antibodies or tumor markers, or see how well-desired treatments work. Blood tests help physicians evaluate the working conditions of organs, diagnose diseases and risk factors for heart disease, check if medicines are working, check for cases of infection or genetic conditions, and determine how well the blood is clotting. Blood tests take only a few minutes and can be done in any local hospital or clinic.
Download a Free Sample To learn more about this report,
Blood Testing Is Expanding Into Less Invasive Disease Detection
The blood testing market is moving toward advanced tests that can identify diseases from biomarkers circulating in blood, reducing the need for more invasive procedures. New assays are increasingly being developed for neurological disorders, cancer, infectious diseases, and chronic conditions, while improvements in molecular testing and immunoassays are supporting earlier detection. This trend is also making blood-based testing more useful in routine clinical settings because samples can be collected more easily than tissue or imaging-based alternatives. As healthcare systems emphasize earlier diagnosis and personalized care, laboratories and diagnostic companies are investing in tests that combine high analytical sensitivity with simpler sample collection and faster clinical decision-making.
In May 2025, the U.S. FDA cleared Fujirebio's Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, the first FDA-cleared blood test to aid diagnosis of Alzheimer's disease.
Growing Demand for Early Disease Detection Is Increasing Routine Blood Testing
The need to detect diseases earlier is supporting demand for blood testing across hospitals, diagnostic laboratories, and primary-care settings. Blood samples can provide measurable information about metabolic health, infection, organ function, cancer-related biomarkers, and other biological changes before symptoms become severe. Earlier results can help clinicians select treatment, monitor disease progression, and reduce unnecessary diagnostic procedures. The expansion of preventive healthcare and screening programs further increases the number of people undergoing laboratory testing. In addition, improvements in automated analyzers and multiplex assays allow laboratories to process more biomarkers from limited samples. These developments are increasing the clinical value of blood testing and supporting broader use across healthcare systems.
In May 2026, WHO convened the Global Diagnostics Coalition for the first time to strengthen access to diagnostics worldwide, highlighting the continuing need to expand timely and reliable testing.
Unequal Laboratory Infrastructure Limits Access to Advanced Blood Testing
Advanced blood testing depends on reliable laboratories, trained personnel, sample transportation, electricity, quality-control systems, and appropriate diagnostic equipment. These requirements can restrict access in rural areas and low-resource healthcare systems, where patients may need to travel long distances to provide samples or receive results. Even when a test is technically available, shortages of laboratory workers and maintenance services can reduce testing capacity. High-end molecular and automated platforms can also be expensive to install and operate compared with basic laboratory methods. These infrastructure limitations can slow adoption of advanced blood tests and create significant differences in diagnostic availability between well-equipped urban healthcare centers and underserved communities.
In June 2026, WHO's Global Status Report on Blood Safety and Availability 2025 identified persistent gaps in laboratory screening, blood-system capacity, and equitable access, particularly in low- and middle-income countries.
Multiplex Testing Can Deliver More Clinical Information From a Single Blood Sample
Multiplex blood testing offers a major opportunity because one sample can be analyzed for multiple biomarkers or pathogens, helping clinicians obtain broader information without repeatedly collecting blood. This approach can support infectious-disease diagnosis, cancer assessment, cardiovascular monitoring, and other conditions where several markers may improve clinical interpretation. Multiplex platforms can also reduce the number of separate laboratory procedures and potentially improve workflow efficiency. As healthcare providers seek faster and more comprehensive diagnostic information, manufacturers can develop panels tailored to specific diseases or clinical pathways. Expansion of multiplex testing into decentralized and near-patient settings could further increase access, particularly where conventional laboratory infrastructure is limited.
In September 2025, WHO announced that it was developing guidelines on multiplex testing, reflecting growing international attention toward tests capable of detecting multiple targets from a single testing process.
Maintaining Consistent Test Quality Across Laboratories Remains Difficult
Blood testing requires strict control of the complete testing process because errors can occur during sample collection, transport, preparation, analysis, or reporting. Differences in instruments, reagents, calibration methods, reference ranges, and laboratory procedures can affect results and make comparisons between facilities difficult. New biomarker tests create additional challenges because laboratories must establish analytical performance, clinical validity, quality controls, and appropriate interpretation before routine use. Maintaining consistency becomes even more important when test results influence major treatment decisions. Diagnostic manufacturers and laboratories therefore need standardized methods, proficiency testing, validated procedures, and continuous quality monitoring to ensure reliable results across different healthcare settings and geographic regions.
In 2025, WHO issued technical guidance for manufacturers seeking prequalification of point-of-care haemoglobin analyzers, covering quantitative detection of haemoglobin in capillary or venous whole blood and emphasizing quality and performance requirements.
The solutions segment dominated the blood testing market with a 78.6% market share, valued at USD 79.15 billion, and recorded a CAGR of 7.58%. Its leading position is supported by the essential role of testing platforms, instruments, reagents, and integrated diagnostic systems in routine laboratory workflows and clinical decision-making.
Request Customizationto receive a tailored report.
The Glucose Testing segment dominated the Blood Testing Market with a 27.8% market share, valued at USD 27.99 billion, and recorded a CAGR of 8.46%. Its dominance is driven by the frequent use of glucose measurements for diabetes screening, treatment monitoring, and metabolic health assessment across hospitals, clinics, and point-of-care settings.
The Automated segment dominated the Blood Testing Market with a 71.9% market share, valued at USD 72.4 billion, and recorded a CAGR of 8.35%. Its strong position reflects the ability of automated analyzers to process high sample volumes, standardize test procedures, reduce manual handling, and support faster laboratory turnaround.
The Hospitals & Clinics segment dominated the Blood Testing Market with a 44.7% market share, valued at USD 45.01 billion, and recorded a CAGR of 7.48%. Its leading share is supported by the continuous need for blood tests in emergency care, inpatient monitoring, preoperative assessment, chronic disease management, and routine clinical diagnosis.
Speak to an Analystto discuss market opportunities.
North America accounted for 38.5% of the Blood Testing Market. The regional market was valued at USD 38.77 billion. It is projected to grow at a CAGR of 7.62% during the forecast period.
The United States blood testing landscape is strongly shaped by CLIA standards, which apply to facilities examining human specimens for diagnosis, prevention, treatment, or health assessment. Moderate- and high-complexity tests face additional requirements for personnel qualifications, quality control, and performance verification, keeping laboratory accuracy central to test adoption.
Canada's blood testing system is closely integrated with provincially organized healthcare and laboratory networks, making clinical testing largely dependent on established diagnostic pathways rather than a single national delivery model. This structure creates demand for testing platforms that can operate efficiently across hospital, public-health, and community laboratory settings.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe represented 28.4% of the Blood Testing Market. Its regional market value stood at USD 28.6 billion. Europe is expected to register a CAGR of 8.74% during the forecast period.
Germany emphasizes targeted laboratory diagnostics, with physicians encouraged to select tests according to specific clinical indications and disease-monitoring requirements. This approach supports blood testing technologies that provide reliable results while helping laboratories reduce unnecessary or repetitive diagnostic procedures.
The United Kingdom is moving more diagnostic activity closer to patients through NHS Community Diagnostic Centres, where phlebotomy and selected point-of-care blood tests form part of the core service model. Expanding these centres reduces reliance on traditional hospital-only testing and creates a distinct pathway for decentralized blood collection and rapid diagnostics.
Asia Pacific held 22.6% of the Blood Testing Market. The regional market generated USD 22.76 billion. It is projected to expand at a CAGR of 8.31% during the forecast period.
Japan generates recurring blood testing demand through mandatory workplace health examinations, which can include anemia, liver-function, blood-lipid, and blood-glucose tests. The regular screening framework gives routine laboratory testing a preventive-health role beyond diagnosis after symptoms appear.
China has strengthened technical standardization across clinical blood testing, including updated requirements covering specimen collection, analytical quality, HbA1c testing, and quantitative laboratory procedures. These standards increase the importance of consistent sample handling and validated analytical performance across clinical laboratories.
Latin America accounted for 6.1% of the Blood Testing Market. The regional market was valued at USD 6.14 billion. It is forecast to grow at a CAGR of 6.92% during the forecast period.
Brazil is extending the role of blood testing into population-level health surveillance, with the 2026 National Health Survey collecting blood and urine samples for the first time. This adds laboratory biomarkers to national monitoring of disease and health risks, creating a different demand base from routine patient diagnostics alone.
The Middle East and Africa represented 4.4% of the Blood Testing Market. The regional market value reached USD 4.43 billion. It is projected to record a CAGR of 6.38% during the forecast period.
The UAE is developing regulated clinical laboratory models that include conventional laboratory operations, walk-in testing, molecular testing, and other specialized diagnostic services. Dubai's laboratory standards place licensing and operational requirements around these formats, supporting a structured environment for blood testing outside a single hospital-based model.
The global blood testing market is highly competitive, with diagnostic manufacturers and laboratory service providers competing across clinical chemistry, immunoassays, hematology, molecular diagnostics, blood screening, infectious disease testing, and point-of-care diagnostics. Key players operating in the industry include Abbott Diagnostics, Bio-Rad Laboratories Inc., Roche Diagnostics, Quest Diagnostics, Danaher Corporation, Becton Dickinson & Company, Biomerica Inc., bioMérieux S.A., Siemens Healthineers, Trinity Biotech PLC, F. Hoffmann-La Roche Ltd., Grifols S.A., Alere Inc., Hologic Inc., and B. Braun Melsungen AG. Roche, Abbott, Siemens Healthineers, Danaher, and Quest Diagnostics have strong positions supported by extensive diagnostic portfolios, laboratory infrastructure, established distribution networks, and continuous assay development.
Industry participants are focusing on laboratory automation, high-throughput testing systems, blood-based biomarkers, molecular diagnostics, artificial intelligence-supported laboratory workflows, and rapid point-of-care testing to strengthen their competitive positions. Companies are also expanding testing menus for neurological disorders, infectious diseases, cancer, and chronic diseases while developing systems that require smaller blood samples and provide faster results. Growing adoption of decentralized diagnostics and demand for earlier disease detection are further encouraging investment in highly automated and scalable blood-testing technologies.
Roche Diagnostics is a prominent participant in the global blood testing market, providing solutions across immunodiagnostics, clinical chemistry, molecular diagnostics, blood screening, tissue diagnostics, and point-of-care testing. The company continues to expand its blood-based biomarker portfolio while using its large installed base of cobas laboratory systems to increase access to advanced diagnostic assays. In the first half of 2026, Roche's Diagnostics Division generated CHF 6.74 billion in sales, with sales increasing 3% at constant exchange rates, supported partly by demand for immunodiagnostic and clinical chemistry products.
In August 2026, Roche received U.S. FDA clearance for its Elecsys pTau217 blood test for assessing amyloid pathology associated with Alzheimer's disease. The assay became the first FDA-cleared single-biomarker blood test supporting both rule-in and rule-out assessment across primary and specialty care and is designed for deployment across more than 4,500 Roche cobas laboratory instruments in the U.S.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com